Results 231 to 240 of about 242,580 (385)

Human Cyclophilins—An Emerging Class of Drug Targets

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova   +3 more
wiley   +1 more source

Nerve Ultrasound in Patients With Friedreich Ataxia

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Nerve enlargement has been reported in patients with Friedreich ataxia (FRDA). The underlying cause remains unclear, and both inflammatory processes and dysmyelination have been suggested as potential mechanisms. This study was aimed at assessing nerve morphology with high‐resolution ultrasound, to identify and describe ...
Katharina Kneer   +9 more
wiley   +1 more source

ABCA1 acts as a protective modulator in amyotrophic lateral sclerosis. [PDF]

open access: yesiScience
Li Q   +7 more
europepmc   +1 more source

MRI of Neurogenic Human Motor Units Following Poliomyelitis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Surviving motor units in neurogenic diseases demonstrate collateral reinnervation. Scanning electromyography (EMG) reveals normal motor unit corridor length, but with “silent regions,” suggesting that reinnervation does not result in increased motor unit size but may increase motor unit complexity.
Stuart Maitland   +6 more
wiley   +1 more source

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy